Connect Biopharma Shares Rise After Rademikibart Shows Rapid Lung Gains and Strong Dermatology Outcomes
Connect Biopharma Holdings saw its stock climb following the release of multiple clinical study results for rademikibart, an anti-interleukin-4-receptor alpha antibody. Preliminary Phase 1 pharmacology data indicate rapid, sustained improvements in lung function after a single 300 mg intravenous dose, while a partner-run Phase 3 trial in China repo…